2. Academic Validation
  3. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors

Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors

  • Mol Cancer Ther. 2014 Nov;13(11):2559-71. doi: 10.1158/1535-7163.MCT-13-1086.
Khalil Dayekh 1,  Stephanie Johnson-Obaseki 2,  Martin Corsten 2,  Patrick J Villeneuve 3,  Harmanjatinder S Sekhon 4,  Johanne I Weberpals 5,  Jim Dimitroulakos 6
Affiliations

Affiliations

  • 1 Centre for Cancer Therapeutics, the Ottawa Hospital Research Institute, The University of Ottawa, Ottawa, Ontario, Canada. Faculty of Medicine and the Department of Biochemistry, The University of Ottawa, Ottawa, Ontario, Canada.
  • 2 Department of Otolaryngology, The Ottawa Hospital, Ottawa, Ontario, Canada.
  • 3 Centre for Cancer Therapeutics, the Ottawa Hospital Research Institute, The University of Ottawa, Ottawa, Ontario, Canada. Department of Thoracic Surgery, The Ottawa Hospital, Ottawa, Ontario, Canada.
  • 4 Department of Pathology and Laboratory Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.
  • 5 Centre for Cancer Therapeutics, the Ottawa Hospital Research Institute, The University of Ottawa, Ottawa, Ontario, Canada. Department of Gynaecologic Oncology, The Ottawa Hospital, Ottawa, Ontario, Canada.
  • 6 Centre for Cancer Therapeutics, the Ottawa Hospital Research Institute, The University of Ottawa, Ottawa, Ontario, Canada. Faculty of Medicine and the Department of Biochemistry, The University of Ottawa, Ottawa, Ontario, Canada. jdimitroulakos@ohri.ca.
PMID: 25189541 DOI: 10.1158/1535-7163.MCT-13-1086
Abstract

Targeting the EGFR, with inhibitors such as erlotinib, represents a promising therapeutic option in advanced head and neck squamous cell carcinomas (HNSCC). However, they lack significant efficacy as single agents. Recently, we identified the ability of statins to induce synergistic cytotoxicity in HNSCC cells through targeting the activation and trafficking of the EGFR. However, in a phase I trial of rosuvastatin and erlotinib, statin-induced muscle pathology limited the usefulness of this approach. To overcome these toxicity limitations, we sought to uncover Other potential combinations using a 1,200 compound screen of FDA-approved drugs. We identified monensin, a coccidial Antibiotic, as synergistically enhancing the cytotoxicity of erlotinib in two cell line models of HNSCC, SCC9 and SCC25. Monensin treatment mimicked the inhibitory effects of statins on EGFR activation and downstream signaling. RNA-seq analysis of monensin-treated SCC25 cells demonstrated a wide array of Cholesterol and lipid synthesis genes upregulated by this treatment similar to statin treatment. However, this pattern was not recapitulated in SCC9 cells as monensin specifically induced the expression of activation of transcription factor (ATF) 3, a key regulator of statin-induced Apoptosis. This differential response was also demonstrated in monensin-treated ex vivo surgical tissues in which HMG-CoA reductase expression and ATF3 were either not induced, induced singly, or both induced together in a cohort of 10 patient samples, including four HNSCC. These results suggest the potential clinical utility of combining monensin with erlotinib in patients with HNSCC.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z